I
Initiator Pharma A/S
STO:INIT
Initiator Pharma A/S
STO:INIT
Price:
2.99
SEK
2.75%
Market Closed
Market Cap:
kr204.7m
Relative Value
The Relative Value of one INIT stock under the Base Case scenario is 5.68 SEK. Compared to the current market price of 2.99 SEK, Initiator Pharma A/S is Undervalued by 47%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
INIT
Relative Value
Base Case
5.68
SEK
Undervaluation 47%
I
Multiples Across Competitors
INIT Competitors Multiples
Initiator Pharma A/S Competitors
Initiator Pharma A/S Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| DK |
I
|
Initiator Pharma A/S
STO:INIT
|
204.7m SEK | 0 | -12.3 | -8.6 | -8.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
402.1B USD | 6.6 | 96.1 | 15.8 | 21.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
203.2B USD | 5.5 | 26.3 | 15.1 | 15.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
182B USD | 6.2 | 21.4 | 13.3 | 16.4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117.1B USD | 9.8 | 29.6 | 22.3 | 23.3 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.6B USD | 5.8 | 18.3 | 13.8 | 15.7 | |
| AU |
|
CSL Ltd
ASX:CSL
|
70.2B AUD | 3.2 | 35.7 | 11.7 | 14.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
38.4B EUR | 10.9 | 35.1 | 38.1 | 38.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
